Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE:600594) signed an equity transfer agreement to acquire a 70% stake in Deyang Cancer Hospital Co., Ltd. from Deyang Foji Hospital Management Partnership (Limited Partnership), Deyang Foming Hospital Management Partnership (Limited Partnership) and Deyang Foxiang Management Hospital Partnership (Limited Partnership) for approximately CNY 340 million on October 26, 2021. Under the terms, Guizhou Yibai Pharmaceutical will pay first installment of CNY 30 million within five working days after handling the change of Deyang Cancer's equity to Guizhou Yibai's name and second installment of CNY 305.9 million within 30 working days after the first installment is paid. The transaction will be funded from own funds and bank loans. As of July 31, 2021, Deyang Cancer Hospital reported total assets of CNY 90.6 million and net assets of CNY 58.9 million. On October 26, 2021, Guizhou Yibai Pharmaceutical15th meeting of the 7th Board of Directors and the 14th meeting of the 7th Board of Supervisors approved the transaction. As of November 26, 2021, the company received the "Notice of Approval of Registration of Change" issued by the Administrative Approval Bureau of Jingyang District, Deyang City. All parties to the transaction completed the formalities for the industrial and commercial change registration of 70% of the shares in Deyang Cancer Hospital and obtained a new "business license".